Pharma has much to learn from the surprising boom of telehealth sales of obesity drugs, Novo Nordisk’s CEO Mike Doustdar said at the Endpoints at #JPM26 event on the sidelines of the …
Read More from Endpoints News
#JPM26: Novo Nordisk CEO says pharma can learn from the GLP-1 compounding boom
